Psoriasis: The future

British Journal of Dermatology, Supplement

Volumn 144, Issue 58, 2001, Pages 37-43

  Kirby, B ^a   Griffiths, C E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Genetics; Immunotherapy; Pharmacogenetics; Psoriasis; Psychology

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOKINE; RETINOID; VITAMIN D DERIVATIVE;

CONFERENCE PAPER; DISTRESS SYNDROME; EXCIMER LASER; FUTUROLOGY; GENETIC SUSCEPTIBILITY; IMMUNOTHERAPY; PHARMACOGENETICS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE;

EID: 0035037549     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2001.00037.x     Document Type: Conference Paper

References (72)

1. Advances in psoriasis therapy
2. Inheritance of psoriasis. Analysis of 2035 family histories
3. Natural history of psoriasis in 61 twin pairs
4. Psoriasis of early and late onset: Characterization of two types of psoriasis
5. Identification of a major susceptibility locus on chromosome 6p: Evidence for further disease loci revealed by a two-stage genome-wide search in psoriasis
6. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q
7. Evidence for familial psoriasis maps to chromosome 4q
8. Searching for psoriasis susceptibility genes in Italy: Genome evidence for a new locus on chromosome 1
9. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two new loci (16q and 20p) by genome-wide scan
10. A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele
11. Corneodesmosin gene polymorphism demonstrates strong linkage disequilibrium with HLA and association with psoriasis vulgaris
12. The A5.1 allele of the MHC Class I chain-related gene A is associated with psoriasis vulgaris in Chinese
13. Animal models of psoriasis - What can we learn from them
14. Pharmacogenetics and the practice of medicine
15. Cyclosporine consensus conference: With emphasis on the treatment of psoriasis
16. Response of psoriasis to a lymphocyte-selective toxin (DAB 389 IL-2) suggests a primary immune but not keratinocyte pathogenic basis
17. Cutaneous leucocyte trafficking and psoriasis
18. Immunopharmacologic effects of Amevive (LFA3-TIP) in chronic plaque psoriasis: Selectivity for peripheral memory effector (CD45 RO+ over naïve (CD45 RA+) T cells
19. Effects of a single dose of a humanised monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
20. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
21. Successful treatment of severe psoriasis with basiliximab an interleukin-2 receptor monoclonal antibody
22. Treatment of severe psoriasis with anti-CD 25 monoclonal antibodies
23. T cells involved in psoriasis vulgaris belong to the Th1 subset
24. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
25. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis alpha (Infliximab) on spondyloarthropathy: An open study
26. The clinical role of anti-TNF alpha antibody treatment in Crohn's disease
27. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results and safety
28. Tumour necrosis factor blockers in rheumatoid arthritis
29. Etanercept in the treatment of psoriatic arthritis
30. Interleukin-10 in cutaneous disorders: Implications for its pathophysiological importance and therapeutic use
31. Treatment of severe psoriasis with fumaric acid esters: Scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference
32. Improvement in psoriasis after intradermal administration of killed Mycobacterium vaccae
33. Immunomodulatory effects of peptide T on Th1/Th2 cytokines
34. CD8 + T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes
35. Selection of conserved TCR VDJ rearrangements in chronic psoriasis plaque suggests a common antigen in psoriasis vulgaris
36. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris
37. Papilloma virus and autoimmunity in psoriasis
38. Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis?
39. T-cell receptor peptides in treatment of autoimmune diseases: Rationale and potential
40. Th2 immune regulation induced by T-cell vaccination in patients with T cell vaccination
41. Topical cyclosporin and psoriasis
42. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study
43. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
44. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
45. Cyclosporine, FK-506, rapamycin, and other immunomodulators
46. A double-blind study in patients with severe psoriasis to assess the clinical activity and safety of rapamycin (sirolimus) alone or in association with a reduced dose of cyclospodn
47. Penetration and efficacy of the topical immunosuppressive sirolimus in psoriasis
48. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis
49. New paradigm for the treatment of cancer: The role of anti-angiogenesis agents
50. Development of SU5416 a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity as an anti-angiogenic agent
51. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors
52. The 72-kDa and the 92k-DA gelatinases but not their inhibitors TIMP-1 and TIMP-2 are expressed in early psoriatic lesions
53. Identification of receptors for retinoids as members of the steroid and thyroid hormone receptor family
54. Current use and future potential role of retinoids in dermatology
55. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer
56. Inhibition of the metabolism of endogenous retinoic acid as treatment for psoriasis: An open study with oral liarozole
57. A double blind placebo-controlled study of oral liarozole in the treatment of palmoplantar pustular psoriasis
58. The effects of oral liarazole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin
59. Recent developments in Vitamin D analogues
60. Effect on calcitriol on the production of T-cell derived cytokines in psoriasis
61. The influence of calcitriol and tacalcitol on angiogenesis and vascular endothelial growth factor (VEGF) gene expression
62. Roles of PPARs in health and disease
63. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferation activated receptor gamma inhibit keratinocyte proliferation
64. Chronic life stress alters sympathetic, neuroendocrine, and immune responsivity to an acute psychological stressor in humans
65. Psoriasis and stress: A prospective study
66. Psychological distress affects the efficacy of PUVA in patients with psoriasis
67. Determinants of psychological distress and its course in the after diagnosis in rheumatoid arthritis patients
68. Cognitive-behavioural management of psoriasis
69. Photodynamic therapy
70. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy
71. 308-nm excimer laser for the treatment of psoriasis: A dose response study
72. Treatment of psoriasis with the pulsed dye laser